Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ian Elliott Krop, M.D.,Ph.D.


This page shows the publications co-authored by Ian Krop and Nabihah Tayob.
Connection Strength

  1. Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. J Clin Oncol. 2021 07 20; 39(21):2375-2385.
    View in: PubMed
    Score: 0.241
  2. Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nat Commun. 2021 09 21; 12(1):5563.
    View in: PubMed
    Score: 0.062
  3. A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer. Breast Cancer Res Treat. 2021 Sep; 189(2):411-423.
    View in: PubMed
    Score: 0.061
  4. Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Res Treat. 2021 Aug; 189(1):103-110.
    View in: PubMed
    Score: 0.060
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.